Nxera Pharma Co., Ltd.
SOLTF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $29 | $13 | $16 | $18 |
| % Growth | 125.9% | -18% | -12.1% | – |
| Cost of Goods Sold | $8 | $3 | $1 | $1 |
| Gross Profit | $21 | $10 | $15 | $17 |
| % Margin | 73.6% | 75.7% | 94.1% | 94.7% |
| R&D Expenses | $12 | $10 | $7 | $6 |
| G&A Expenses | $16 | $10 | $4 | $4 |
| SG&A Expenses | $16 | $10 | $4 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1 | -$1 | -$1 | $3 |
| Operating Expenses | $27 | $19 | $11 | $13 |
| Operating Income | -$5 | -$10 | $3 | $4 |
| % Margin | -18.8% | -74.6% | 22.1% | 21.3% |
| Other Income/Exp. Net | $1 | -$1 | -$2 | -$3 |
| Pre-Tax Income | -$5 | -$11 | $1 | $0 |
| Tax Expense | $0 | -$3 | $1 | -$1 |
| Net Income | -$5 | -$7 | $0 | $1 |
| % Margin | -16.8% | -56.3% | 2.5% | 5.7% |
| EPS | -53.95 | -87.18 | 4.67 | 12.53 |
| % Growth | 38.1% | -1,966.8% | -62.7% | – |
| EPS Diluted | -53.95 | -87.17 | 4.63 | 12.4 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $1 | $1 | $0 |
| Interest Expense | $1 | $2 | $1 | $4 |
| Depreciation & Amortization | $4 | $2 | $1 | $1 |
| EBITDA | $0 | -$6 | $3 | $8 |
| % Margin | 0.4% | -44.7% | 20.4% | 46.2% |